Douglas Emmet Drachman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug-Eluting Stents | 6 | 2021 | 726 | 1.480 |
Why?
|
| Peripheral Arterial Disease | 13 | 2021 | 1175 | 1.400 |
Why?
|
| Angioplasty, Balloon | 5 | 2019 | 732 | 1.390 |
Why?
|
| Lower Extremity | 7 | 2019 | 1022 | 1.140 |
Why?
|
| Cardiology | 9 | 2021 | 1626 | 1.070 |
Why?
|
| Femoral Artery | 4 | 2019 | 947 | 1.030 |
Why?
|
| Stents | 12 | 2017 | 3281 | 1.030 |
Why?
|
| Radial Artery | 3 | 2019 | 203 | 0.740 |
Why?
|
| Endovascular Procedures | 8 | 2021 | 1911 | 0.720 |
Why?
|
| Coronary Restenosis | 3 | 2009 | 424 | 0.710 |
Why?
|
| Vascular Diseases | 3 | 2017 | 1135 | 0.710 |
Why?
|
| Popliteal Artery | 3 | 2019 | 389 | 0.680 |
Why?
|
| Education, Distance | 1 | 2021 | 250 | 0.650 |
Why?
|
| Coronary Vessel Anomalies | 2 | 2017 | 315 | 0.640 |
Why?
|
| Education, Medical, Continuing | 2 | 2021 | 863 | 0.630 |
Why?
|
| Tunica Intima | 2 | 2014 | 496 | 0.630 |
Why?
|
| Cholecystitis | 1 | 2017 | 186 | 0.620 |
Why?
|
| Paclitaxel | 4 | 2021 | 1625 | 0.600 |
Why?
|
| Ischemia | 5 | 2021 | 1904 | 0.600 |
Why?
|
| Congresses as Topic | 1 | 2021 | 784 | 0.600 |
Why?
|
| Gallbladder | 1 | 2017 | 309 | 0.600 |
Why?
|
| Coronary Angiography | 5 | 2020 | 4323 | 0.590 |
Why?
|
| Cholelithiasis | 1 | 2017 | 417 | 0.590 |
Why?
|
| Cardiovascular Agents | 2 | 2021 | 864 | 0.580 |
Why?
|
| Ankle Brachial Index | 1 | 2015 | 166 | 0.550 |
Why?
|
| Hemorrhage | 3 | 2019 | 3189 | 0.520 |
Why?
|
| Coronary Artery Disease | 7 | 2019 | 6101 | 0.510 |
Why?
|
| Renal Artery Obstruction | 2 | 2013 | 292 | 0.510 |
Why?
|
| Intestine, Large | 1 | 2012 | 81 | 0.480 |
Why?
|
| Splanchnic Circulation | 1 | 2012 | 106 | 0.470 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 2012 | 100 | 0.460 |
Why?
|
| Vena Cava Filters | 1 | 2015 | 272 | 0.460 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2014 | 344 | 0.450 |
Why?
|
| Inservice Training | 1 | 2015 | 403 | 0.450 |
Why?
|
| Angioplasty | 2 | 2012 | 403 | 0.450 |
Why?
|
| Certification | 1 | 2015 | 409 | 0.430 |
Why?
|
| Renal Artery | 1 | 2013 | 414 | 0.410 |
Why?
|
| American Heart Association | 5 | 2018 | 955 | 0.410 |
Why?
|
| Coronary Occlusion | 1 | 2013 | 271 | 0.400 |
Why?
|
| Device Removal | 1 | 2015 | 654 | 0.390 |
Why?
|
| Chest Pain | 1 | 2017 | 1089 | 0.390 |
Why?
|
| Cardiac Tamponade | 1 | 2010 | 168 | 0.380 |
Why?
|
| Myocardial Ischemia | 2 | 2017 | 2088 | 0.370 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2010 | 116 | 0.360 |
Why?
|
| Advisory Committees | 4 | 2017 | 758 | 0.360 |
Why?
|
| Radiography, Interventional | 2 | 2014 | 1094 | 0.360 |
Why?
|
| Vascular Surgical Procedures | 2 | 2015 | 1503 | 0.360 |
Why?
|
| Pericardial Effusion | 1 | 2010 | 235 | 0.360 |
Why?
|
| Coronary Stenosis | 1 | 2014 | 799 | 0.350 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2014 | 1853 | 0.350 |
Why?
|
| Carotid Stenosis | 4 | 2016 | 851 | 0.340 |
Why?
|
| Exercise Test | 1 | 2015 | 2115 | 0.330 |
Why?
|
| Coronary Vessels | 2 | 2015 | 2941 | 0.300 |
Why?
|
| Recombinant Proteins | 2 | 2016 | 6939 | 0.300 |
Why?
|
| Venous Thrombosis | 1 | 2015 | 1225 | 0.300 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2006 | 49 | 0.300 |
Why?
|
| Carotid Artery Diseases | 1 | 2012 | 922 | 0.300 |
Why?
|
| Catheterization, Peripheral | 2 | 2019 | 356 | 0.280 |
Why?
|
| Vena Cava, Superior | 1 | 2006 | 182 | 0.280 |
Why?
|
| Treatment Outcome | 20 | 2021 | 61748 | 0.260 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 2360 | 0.230 |
Why?
|
| Amputation | 4 | 2021 | 796 | 0.220 |
Why?
|
| Disease Management | 4 | 2017 | 2537 | 0.220 |
Why?
|
| Clinical Competence | 3 | 2015 | 4606 | 0.200 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2017 | 590 | 0.190 |
Why?
|
| Humans | 53 | 2021 | 706092 | 0.190 |
Why?
|
| Drug Delivery Systems | 2 | 2002 | 2282 | 0.180 |
Why?
|
| Cardiovascular Diseases | 2 | 2021 | 13980 | 0.170 |
Why?
|
| Societies, Medical | 4 | 2020 | 3651 | 0.170 |
Why?
|
| Atherosclerosis | 1 | 2012 | 3171 | 0.160 |
Why?
|
| Endarterectomy | 1 | 2017 | 208 | 0.160 |
Why?
|
| Constriction, Pathologic | 2 | 2017 | 1001 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 7494 | 0.150 |
Why?
|
| Embolic Protection Devices | 1 | 2016 | 46 | 0.150 |
Why?
|
| Registries | 4 | 2019 | 7991 | 0.150 |
Why?
|
| Balloon Occlusion | 1 | 2016 | 126 | 0.150 |
Why?
|
| Myocardial Infarction | 2 | 2014 | 11264 | 0.150 |
Why?
|
| Hirudins | 1 | 2016 | 173 | 0.140 |
Why?
|
| Intracranial Embolism | 1 | 2016 | 214 | 0.140 |
Why?
|
| Limb Salvage | 3 | 2021 | 440 | 0.130 |
Why?
|
| Consensus | 6 | 2019 | 2645 | 0.130 |
Why?
|
| Patient Readmission | 2 | 2018 | 2929 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2002 | 2068 | 0.130 |
Why?
|
| Acute Coronary Syndrome | 2 | 2018 | 2189 | 0.120 |
Why?
|
| Cerebral Revascularization | 1 | 2015 | 227 | 0.120 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2015 | 463 | 0.120 |
Why?
|
| Equipment Failure | 1 | 2015 | 583 | 0.120 |
Why?
|
| Databases, Factual | 3 | 2018 | 7769 | 0.120 |
Why?
|
| Tetraethylammonium Compounds | 1 | 1991 | 32 | 0.120 |
Why?
|
| Tomography, Emission-Computed | 2 | 2015 | 1153 | 0.120 |
Why?
|
| Postoperative Hemorrhage | 1 | 2016 | 419 | 0.120 |
Why?
|
| Nuclear Medicine | 1 | 2015 | 228 | 0.120 |
Why?
|
| Electric Countershock | 1 | 2015 | 514 | 0.110 |
Why?
|
| Heart Diseases | 2 | 2015 | 2741 | 0.110 |
Why?
|
| Diabetes Mellitus | 2 | 2021 | 5191 | 0.110 |
Why?
|
| 4-Aminopyridine | 1 | 1991 | 74 | 0.110 |
Why?
|
| Male | 19 | 2020 | 351181 | 0.110 |
Why?
|
| Coronary Aneurysm | 1 | 2014 | 220 | 0.110 |
Why?
|
| Academies and Institutes | 1 | 2013 | 297 | 0.110 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2015 | 845 | 0.110 |
Why?
|
| Ultrasonography, Interventional | 1 | 2019 | 1469 | 0.110 |
Why?
|
| Heparin | 2 | 2016 | 1614 | 0.100 |
Why?
|
| Cross Infection | 1 | 2020 | 1407 | 0.100 |
Why?
|
| Electrocardiography | 2 | 2017 | 6397 | 0.100 |
Why?
|
| Endarterectomy, Carotid | 1 | 2015 | 546 | 0.100 |
Why?
|
| Time Factors | 11 | 2021 | 41245 | 0.100 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2017 | 2964 | 0.100 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2018 | 1151 | 0.090 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2018 | 1291 | 0.090 |
Why?
|
| Renal Dialysis | 1 | 2018 | 1675 | 0.090 |
Why?
|
| Hypertension, Renovascular | 1 | 2009 | 137 | 0.090 |
Why?
|
| Female | 18 | 2020 | 376249 | 0.090 |
Why?
|
| Potassium Channels | 1 | 1991 | 575 | 0.090 |
Why?
|
| Lidocaine | 1 | 1991 | 543 | 0.090 |
Why?
|
| Sirolimus | 2 | 2009 | 1572 | 0.090 |
Why?
|
| Pipecolic Acids | 1 | 2008 | 72 | 0.090 |
Why?
|
| Bupivacaine | 1 | 1991 | 424 | 0.090 |
Why?
|
| Membrane Potentials | 1 | 1991 | 1191 | 0.090 |
Why?
|
| Risk Factors | 12 | 2021 | 70041 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 1869 | 0.080 |
Why?
|
| Communication | 1 | 2021 | 3370 | 0.080 |
Why?
|
| Alcoholism | 1 | 2017 | 1835 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 6563 | 0.080 |
Why?
|
| Equipment Design | 1 | 2015 | 3635 | 0.080 |
Why?
|
| Ultrasonography | 2 | 2017 | 5899 | 0.080 |
Why?
|
| Acute Disease | 1 | 2017 | 7195 | 0.080 |
Why?
|
| Education, Medical, Graduate | 2 | 2015 | 2148 | 0.070 |
Why?
|
| United States | 14 | 2021 | 66938 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2018 | 2526 | 0.070 |
Why?
|
| Curriculum | 2 | 2015 | 3296 | 0.070 |
Why?
|
| Coronary Disease | 1 | 2000 | 6119 | 0.070 |
Why?
|
| Inflammation | 1 | 2005 | 9895 | 0.070 |
Why?
|
| Phlebography | 1 | 2006 | 329 | 0.070 |
Why?
|
| Vascular Patency | 2 | 2019 | 904 | 0.070 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 15281 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2013 | 1653 | 0.060 |
Why?
|
| Stroke | 3 | 2015 | 9182 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2016 | 5127 | 0.060 |
Why?
|
| Aged, 80 and over | 9 | 2018 | 58656 | 0.060 |
Why?
|
| Hemodynamics | 2 | 2010 | 4196 | 0.060 |
Why?
|
| Catheter Ablation | 1 | 2015 | 2454 | 0.060 |
Why?
|
| Heart Ventricles | 1 | 2015 | 3831 | 0.060 |
Why?
|
| Brain Ischemia | 1 | 2016 | 3258 | 0.060 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3156 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 13356 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3269 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2008 | 1132 | 0.050 |
Why?
|
| Pandemics | 1 | 2020 | 6819 | 0.050 |
Why?
|
| Ulnar Artery | 1 | 2019 | 17 | 0.050 |
Why?
|
| Immunosuppressive Agents | 2 | 2005 | 4209 | 0.050 |
Why?
|
| Patient Selection | 3 | 2018 | 4320 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2010 | 1999 | 0.050 |
Why?
|
| African Americans | 1 | 2015 | 5208 | 0.050 |
Why?
|
| Swine | 1 | 2009 | 5733 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 2018 | 14986 | 0.040 |
Why?
|
| Laboratories, Hospital | 1 | 2020 | 199 | 0.040 |
Why?
|
| Critical Illness | 2 | 2021 | 2451 | 0.040 |
Why?
|
| Models, Animal | 1 | 2005 | 2210 | 0.040 |
Why?
|
| Hospital Mortality | 3 | 2020 | 5102 | 0.040 |
Why?
|
| Incidence | 4 | 2018 | 20514 | 0.040 |
Why?
|
| Animals | 6 | 2014 | 170274 | 0.040 |
Why?
|
| Punctures | 1 | 2018 | 371 | 0.040 |
Why?
|
| Vasoconstriction | 1 | 2019 | 608 | 0.040 |
Why?
|
| Risk Assessment | 3 | 2014 | 23486 | 0.040 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 1995 | 51 | 0.040 |
Why?
|
| Arrestins | 1 | 1995 | 81 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2019 | 836 | 0.030 |
Why?
|
| Credentialing | 1 | 2015 | 130 | 0.030 |
Why?
|
| Retrospective Studies | 6 | 2021 | 70699 | 0.030 |
Why?
|
| Mentors | 1 | 2020 | 596 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2005 | 1801 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2017 | 707 | 0.030 |
Why?
|
| Recurrence | 2 | 2009 | 8258 | 0.030 |
Why?
|
| Polymers | 1 | 2002 | 1653 | 0.030 |
Why?
|
| Rabbits | 1 | 2000 | 5239 | 0.030 |
Why?
|
| Antithrombins | 1 | 2016 | 286 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2017 | 589 | 0.030 |
Why?
|
| Benchmarking | 1 | 2019 | 906 | 0.030 |
Why?
|
| Aged | 8 | 2018 | 162244 | 0.030 |
Why?
|
| Algorithms | 1 | 2014 | 13596 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2018 | 1839 | 0.030 |
Why?
|
| Morbidity | 1 | 2018 | 1686 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2008 | 4232 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 1995 | 528 | 0.030 |
Why?
|
| Tetraethylammonium | 1 | 1991 | 60 | 0.030 |
Why?
|
| Rana catesbeiana | 1 | 1991 | 89 | 0.030 |
Why?
|
| Models, Educational | 1 | 2015 | 396 | 0.030 |
Why?
|
| Isotonic Solutions | 1 | 1991 | 118 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 4675 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 20276 | 0.030 |
Why?
|
| Comorbidity | 2 | 2017 | 10606 | 0.030 |
Why?
|
| Solutions | 1 | 1991 | 417 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 1995 | 946 | 0.030 |
Why?
|
| Leadership | 1 | 2020 | 1305 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 39335 | 0.030 |
Why?
|
| Pacemaker, Artificial | 1 | 2015 | 756 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2012 | 553 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 18314 | 0.020 |
Why?
|
| Inpatients | 1 | 2021 | 2172 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 9452 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2009 | 239 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2014 | 676 | 0.020 |
Why?
|
| Sciatic Nerve | 1 | 1991 | 624 | 0.020 |
Why?
|
| Adult | 3 | 2017 | 211817 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2006 | 4835 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2015 | 1267 | 0.020 |
Why?
|
| Teaching | 1 | 2015 | 1194 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 3592 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2014 | 2129 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2020 | 10585 | 0.020 |
Why?
|
| Fibrinolytic Agents | 1 | 2016 | 2119 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 8024 | 0.020 |
Why?
|
| Arginine | 1 | 2008 | 949 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 3691 | 0.020 |
Why?
|
| Action Potentials | 1 | 1991 | 1782 | 0.020 |
Why?
|
| Survival Rate | 1 | 2018 | 13364 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2015 | 2007 | 0.020 |
Why?
|
| Middle Aged | 5 | 2017 | 215044 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 12395 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2014 | 10004 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 3080 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 12514 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2008 | 1940 | 0.010 |
Why?
|
| Logistic Models | 1 | 2014 | 13601 | 0.010 |
Why?
|
| Radiography | 1 | 2009 | 6987 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2013 | 8984 | 0.010 |
Why?
|
| beta-Adrenergic Receptor Kinases | 1 | 1995 | 7 | 0.010 |
Why?
|
| Bucladesine | 1 | 1995 | 127 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1995 | 881 | 0.010 |
Why?
|
| Kidney | 1 | 2009 | 6824 | 0.010 |
Why?
|
| Cricetulus | 1 | 1995 | 851 | 0.010 |
Why?
|
| Prognosis | 1 | 2012 | 29031 | 0.010 |
Why?
|
| Eye Proteins | 1 | 1995 | 664 | 0.010 |
Why?
|
| Cricetinae | 1 | 1995 | 2591 | 0.010 |
Why?
|
| DNA Primers | 1 | 1995 | 3042 | 0.010 |
Why?
|
| Antigens | 1 | 1995 | 1530 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2012 | 50549 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 1984 | 7064 | 0.000 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 1984 | 95 | 0.000 |
Why?
|
| Phosphorylation | 1 | 1995 | 8738 | 0.000 |
Why?
|
| Base Sequence | 1 | 1995 | 13464 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 14357 | 0.000 |
Why?
|
| Psychological Tests | 1 | 1984 | 652 | 0.000 |
Why?
|
| Gene Expression | 1 | 1995 | 8063 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1995 | 18913 | 0.000 |
Why?
|
| Cell Line | 1 | 1995 | 16794 | 0.000 |
Why?
|